Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 50Lymphoma 6Recurrence 3Waldenstrom Macroglobulinemia 2Plasmacytoma 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Neoplasms 2Amyloidosis 2Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1POEMS Syndrome 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Hematologic Diseases 1Graft vs Host Disease 1Glioblastoma 1Chromosome 17 deletion 1Alzheimer Disease 1Advanced Non-hematologic Malignancies 1Advanced Cancers 1

Interventions

venetoclax 4fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 3ibrutinib 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Melphalan 2Dexamethasone 2pomalidomide 1pembrolizumab 1obinutuzumab 1ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1carmustine, poliferprosan 20 drug combination 1auricularum 1acalabrutinib 1Sirolimus 1RG7388 1Nivolumab 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1Carmustine 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Chromosome 17 deletion × ixazomib × Clear all
NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
33 enrolled 26 charts
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡